Sivextro approved for adult skin infections

Sivextro approved for adult skin infections

(HealthDay)—The antibiotic Sivextro (tedizolid phosphate) has been approved by the U.S. Food and Drug Administration to treat adults with skin infections.

The drug, which may be taken intravenously or orally as a pill, is designed to treat infections including methicillin-resistant Staphylococcus aureus (MRSA), the FDA said in a news release.

The drug's safety and effectiveness were evaluated in clinical studies involving more than 1,300 adults with serious-to-severe . The most common side effects recorded were nausea, headache, diarrhea, vomiting and dizziness. The drug was not evaluated among adults with neutropenia, the agency said.

Sivextro is the second new antibiotic for skin infections to be FDA-approved in the past month, following the May 23 approval of Dalvance (dalbavancin).

Sivextro is marketed by Cubist Pharmaceuticals, baaed in Lexington, Mass.

More information: More Information

Related Stories

Vibativ approved for certain bacterial pneumonia

date Jun 24, 2013

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Impavido approved to treat tropical parasitic disease

date Mar 20, 2014

(HealthDay)—Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical disease caused by a parasite that's transmitted by the bites of sand flies.

Aptiom approved to treat seizures

date Nov 11, 2013

(HealthDay)—Aptiom (eslicarbazepine acetate) has been approved by the U.S. Food and Drug Administration as an add-on drug to help treat adults with partial epileptic seizures.

Recommended for you

Study supports HPV vaccination guidelines

date 3 hours ago

(HealthDay)—New research finds that young women who get the HPV vaccine gain significant protection against infection in three parts of the body if they haven't already been exposed to the human papillomavirus.

Teva offers to buy Mylan in $40.1B cash-and-stock deal

date 7 hours ago

Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring ...

FDA warns of bogus botox

date Apr 20, 2015

(HealthDay)—Counterfeit Botox may have been distributed to doctors' offices and medical clinics across the United States, the U.S. Food and Drug Administration warns.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.